DB05912ExperimentalSmall molecule
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
- Mechanism
- Curator reviewed
REN-850 acts by inhibiting leukocyte trafficking and modulating the cell migration driven by multiple chemokine receptors. The oral administration of REN-850 significantly reduces severity of outcomes in multiple in vivo models of multiple Sclerosis (MS) and rheumatoid arthritis (RA).
- Primary indication
- Investigated for use/treatment in multiple sclerosis.Curator reviewed
- Code names
- REN-850
Which companies are running trials of REN-850, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account